Vir Biotechnology, GSK Terminate Collaboration on Flu
By Denny Jacob
Vir Biotechnology and GSK terminated their collaboration regarding the flu.
The clinical-stage immunology company and GSK collaborated to research, develop and commercialize Vir's monoclonal antibodies for the prevention, treatment or prophylaxis of the influenza virus under an agreement established in May 2021.
Vir said the change reflects that it retains sole rights to continue advancing its investigational therapies for influenza independently or with other partners. The company added that it's actively pursuing external partnership opportunities for its next-generation influenza A and B antibodies and antibody drug conjugates.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 22, 2024 16:57 ET (21:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued